Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Ahn

Showing results (91-100 of 121) with videos related to

Pageof 13
Sort By:
Plos One|November 28, 2012
SERPINB3 in the chicken model of ovarian cancer: a prognostic factor for platinum resistance and survival in patients with epithelial ovarian cancerWhasun Lim, Hee Seung Kim, Wooyoung Jeong, et al.
Blood|May 11, 2018
A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib eraHannah R Robinson, Junpeng Qi, Erika M Cook, et al.
Blood Advances|February 14, 2022
BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLLChristopher Pleyer, Kerry J Laing, Mir A Ali, et al.
American Journal of Hematology|August 19, 2020
A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemiaChristopher Pleyer, Xin Tian, Shakuntala Rampertaap, et al.
Blood Advances|January 4, 2018
Early progression of disease as a predictor of survival in chronic lymphocytic leukemiaInhye E Ahn, Charles M Farber, Matthew S Davids, et al.
Molecular Biology of the Cell|May 30, 2009
The first propeller domain of LRP6 regulates sensitivity to DKK1Minke E Binnerts, Nenad Tomasevic, Jessica M Bright, et al.
Blood Advances|June 23, 2026
SAVE, Safe Accelerated Venetoclax Escalation: A phase Ib study of obinutuzumab plus venetoclax with daily ramp-up in CLLJennifer L Crombie, Inhye E Ahn, Yue Ren, et al.
Oncotarget|October 6, 2015
HER2 as a novel therapeutic target for cervical cancerDoo-Yi Oh, Seokhwi Kim, Yoon-La Choi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2023
CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor TherapyAnfal Alsadhan, Jonathan Chen, Erika M Gaglione, et al.
Blood|December 17, 2025
A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 StudyAndy Itsara, Victoria M Rogness, Laura Samples, et al.
Pageof 13

Showing results (91-100 of 121) with videos related to

Sort By:
Pageof 13
Plos One|November 28, 2012
SERPINB3 in the chicken model of ovarian cancer: a prognostic factor for platinum resistance and survival in patients with epithelial ovarian cancerWhasun Lim, Hee Seung Kim, Wooyoung Jeong, et al.
Blood|May 11, 2018
A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib eraHannah R Robinson, Junpeng Qi, Erika M Cook, et al.
Blood Advances|February 14, 2022
BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLLChristopher Pleyer, Kerry J Laing, Mir A Ali, et al.
American Journal of Hematology|August 19, 2020
A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemiaChristopher Pleyer, Xin Tian, Shakuntala Rampertaap, et al.
Blood Advances|January 4, 2018
Early progression of disease as a predictor of survival in chronic lymphocytic leukemiaInhye E Ahn, Charles M Farber, Matthew S Davids, et al.
Molecular Biology of the Cell|May 30, 2009
The first propeller domain of LRP6 regulates sensitivity to DKK1Minke E Binnerts, Nenad Tomasevic, Jessica M Bright, et al.
Blood Advances|June 23, 2026
SAVE, Safe Accelerated Venetoclax Escalation: A phase Ib study of obinutuzumab plus venetoclax with daily ramp-up in CLLJennifer L Crombie, Inhye E Ahn, Yue Ren, et al.
Oncotarget|October 6, 2015
HER2 as a novel therapeutic target for cervical cancerDoo-Yi Oh, Seokhwi Kim, Yoon-La Choi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2023
CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor TherapyAnfal Alsadhan, Jonathan Chen, Erika M Gaglione, et al.
Blood|December 17, 2025
A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 StudyAndy Itsara, Victoria M Rogness, Laura Samples, et al.
Pageof 13